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ImmunohistochemistryAbstract Background: A disintegrin and metalloprotease 8 (ADAM8) is a trans-membrane
protein, which is involved in cell adhesion, signaling and migration as well as the proteolytic cleav-
age of various substrates. Endostatin is a potent inhibitor of angiogenesis. ADAM8 and Endostatin
have been associated with multiple malignancies. However, their role in osteosarcoma is not fully
elucidated.
Aim: To determine the expression of ADAM8 and endostatin in osteosarcoma and to study their
correlation with different clinicopathological parameters and patients’ outcomes.
Material and methods: ADAM8 and endostatin expression were immunohistochemically evaluated
in 61 primary osteosarcomas and 11 pulmonary metastatic osteosarcoma lesions.
Results: Among 61 primary osteosarcomas, ADAM8 was detected in 52 tumors (85.2%) and
highly expressed in 33 cases (54.1%). Positive endostatin expression was found in 28 tumors
(45.9%). Higher ADAM8 and decreased endostatin expression rates in metastatic lesions compared
to primary osteosarcoma were found but these differences were not statistically signiﬁcant
(p= 0.086 & 0.558 respectively). High ADAM8 expression score and positive endostatin expression
were signiﬁcantly correlated with tumor size, stage and distant metastasis (p< 0.05). Survival anal-
ysis showed that high ADAM8 expression was associated with poor overall survival (OS)
(p= 0.0002). Multivariate analysis revealed that ADAM8 expression level was an independent
prognostic parameter for the OS (p= 0.017).
Conclusion: Our data suggest that ADAM8 and endostatin play a role in osteosarcoma progression.
High ADAM8 expression serves as a reliable marker for poor prognosis in osteosarcoma patients.
ª 2014 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.Introduction
Osteosarcoma (OS) is the most common, nonhematopoietic,
primary bone malignancy particularly among children and
adolescents with a second incidence peak in the elderly [1].
Table 1 Clinicopathological features of 61
primary osteosarcoma cases.
Clinicopathological features n (%)
Age
618 years 33 (54.1%)
>18 years 28 (45.9%)
Gender
Male 38 (62.3%)
Female 23 (37.7%)
Tumor site
Extremities 54 (88.5%)
Axial 7 (11.5%)
Tumor type
Osteoblastic 39 (63.9%)
Chondroblastic 17 (27.9%)
Fibroblastic 7 (8.2%)
Tumor size
68 cm 24 (39.3%)
>8 cm 37 (60.7%)
Stage
IA 6 (9.8%)
IB 7 (11.5%)
IIA 10 (16.4%)
IIB 26 (42.6%)
III 12 (19.7%)
Metastasis at diagnosis
No 49 (80.3%)
Yes 12 (19.7%)
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mary malignant bone tumors [2].
Osteosarcoma is a devastating tumor, characterized by high
local aggressiveness, rapid growth rate and early metastasis to
lungs and distant bones [3]. The ability of osteosarcoma cells
to invade and metastasize depends on dynamic changes
including cell–cell and cell–matrix interactions. The extracellu-
lar matrix degradation is an essential process for tumor cell
invasion and angiogenesis [3]. Tumor angiogenesis, in turn,
is crucial for sustained osteosarcoma growth and dissemina-
tion [3,4].
Despite signiﬁcant improvements made over the past
decades in the therapeutic approach of osteosarcoma, patients
with metastases still have a much worse outcome [5]. A better
understanding of the mechanisms contributing to the
progression of osteosarcoma provides novel opportunities for
the effective diagnosis, prognosis, and tumor-targeted
therapies.
A disintegrin and metalloprotease (ADAM) family is a
group of multidomain proteins consisting of pro-peptide,
metalloprotease, disintegrin-like, cysteine rich, EGF-like,
transmembrane and cytoplasmic domains. ADAM8 (CD156)
is a transmembrane protein that belongs to ADAM family.
Within its metalloproteinase domain, ADAM8 possesses the
HEXXXHXXGXXH motif required for proteolytic activity
while the disintegrin domain is involved in binding to integrins,
thereby promoting cellular interactions. It is a multifunctional
protein involved in many biological functions including cell
adhesion, signaling and migration. It is also, involved in the
proteolytic cleavage of various substrates such as cytokine
receptors, their ligands, cell adhesion molecules and extracellu-
lar matrix components [6,7].
ADAM8 is expressed primarily on immune cells and can be
induced with various pro-inﬂammatory stimuli [8]. Its
expression was detected under several pathological conditions
characterized by inﬂammation and extracellular matrix remod-
eling, including cancer [7]. Upregulation of ADAM8 has been
reported in different types of cancers including prostate,
breast, hepatocellular carcinomas and pediatric medulloblas-
toma [9–12].
Endostatin, a recently discovered potent anti-angiogenic
factor, generated from the proteolytic cleavage of collagen
XVIII that is localized in the vascular and epithelial basement
membranes of various organs. Proteolytic degradation of the
subendothelial basement membrane releases antiangiogenic
fragments that oppose the neoangiogenesis in areas of induced
angiogenesis via a negative effect on endothelial cell prolifera-
tion and migration [13,14].
Despite its potent antiangiogenic role, elevated levels of
serum and/or tissue endostatin have been reported to be asso-
ciated with aggressive features and poor prognosis in several
tumors [15–18] making studying of endostatin expression a
subject of interest for several investigators.
Unlike chemotherapeutics, endostatin has no toxicity
effect because it acts on the endothelial cells that line blood
vessels without harming other cells. Moreover, cancers do
not become resistant to endostatin, because endothelial cells
divide slowly, making them unlikely to acquire mutations
that confer drug resistance [19,20]. Furthermore, antiangio-
genic therapy using endostatin has the potential to prevent
post-operative progression of pulmonary metastasis from
osteosarcoma [21].The expression pattern of ADAM8 and endostatin and
their role in osteosarcoma progression is still unclear. The
present work studied the immunohistochemical expression of
ADAM8 and endostatin in primary osteosarcoma and pul-
monary metastatic osteosarcoma lesions and further investi-
gated their clinicopathological and the prognostic values in
this tumor.Materials and methods
Patients and tissue samples
Sixty-one primary osteosarcoma cases were collected from
Pathology Department, Minia University Hospital and Minia
Oncology Center, El-Minia, Egypt, during the period from
2009 to 2013. The corresponding clinical information and fol-
low up data were obtained from patients’ medical records and
presented in Table 1. Of 61 patients, there were 38 male and 23
female patients with a mean age of 24.59 ± 17.18 years and
median 18 years (range, 9–69 years). Fifty-four cases had
osteosarcoma in the extremities and 7 cases had osteosarcoma
in axial skeleton. The resected specimens were reviewed histo-
logically to conﬁrm pathological diagnosis. Staging, using
Musculoskeletal Tumor Society (Enneking) staging system
for malignant bone lesions, was determined according to estab-
lished criteria [22]. Overall survival was calculated in months
from the date of diagnosis and ended with the time of the
tumor-related death or the last follow-up visit of the patient.
Another group of 11 excised metastatic pulmonary lesions
A B
C D 
E F 
Figure 1 (A)–(F): Immunohistochemical expression of ADAM8 and endostatin in primary and metastatic osteosarcoma. (A): High
expression score of ADAM8 in primary osteosarcoma. (B): Low expression score of ADAM8 in primary osteosarcoma. (C): Positive
endostatin expression in primary osteosarcoma. (D): Positive endostatin expression in tumor associated blood vessels. (E): High ADAM8
expression in metastatic lesions. (F): Positive endostatin expression in metastatic lesions. Immunohistochemistry: Diaminobenzidine
(DAB) chromogen and Mayer’s hematoxylin counterstaining. Original magniﬁcations are 400·.
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performed on archived parafﬁn wax embedded specimens.
Immunohistochemical analysis
Immunohistochemistry was performed on sections of 5 lm
thickness from each parafﬁn-embedded specimen. The sections
were dewaxed in xylene and rehydrated at graded alcohol.
Endogenous peroxide was blocked with 0.3% hydrogen perox-
ide in methanol for 30 min at room temperature. For antigenretrieval, sections were pretreated in a microwave oven in cit-
rate buffer solution (pH 6) for 10 min and then left at room
temperature for 20 min. The slides were then incubated at
4 C overnight with the primary antibodies: monoclonal
mouse anti-human endostatin antibody (1837-46), diluted at
1:100, ThermoFisher Scientiﬁc and monoclonal mouse
ADAM8 antibody (MAA620Hu22), diluted at 1:100, Life-
Science Inc. Secondary antibody for 30 min was used, followed
by color detection using a DAB kit. Sections were counter-
stained with Mayer’s hematoxylin, dehydrated in ethanol,
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generated by using phosphate buffered solution (PBS) to
replace the primary antibody. Sections of human placenta
and kidney tissues were used as the positive control for endo-
statin and ADAM8 respectively.
Scoring of immunostaining
Immunostaining was scored by two independent pathologists,
who were blinded to the clinicopathological parameters and
clinical outcomes of the patients. The scores of the two pathol-
ogists were compared and any discrepant scores were trained
through re-examining the staining by both pathologists to
achieve a consensus score.
The expression pattern of ADAM8 was heterogenous.
Therefore, the immunoreactivity score for ADAM8 was based
on two parameters: the proportion of positive cells and the
intensity of immunoreactivity according to previous studies
[10,23]. The number of positive-staining cells showing
immunoreactivity in ten representative random microscopic
ﬁelds was counted and the percentage of positive cells was cal-
culated. The frequency of ADAM8 immunoreactivity in tissue
sections was evaluated as ‘0’ when no positive cells were
observed within the tumor, ‘1’ when <25% of the tumor cells
were positive, ‘2’ when 25% to 50% of the tumor cells were
positive, ‘3’ when 50% to 75% of tumor cells were positive
and ‘4’ when >75% of tumor cells were positive. The intensity
of staining was evaluated as 0, 1, 2, and 3 for no staining, weak
staining, moderate staining, and strong staining, respectively.
A total score of 0–12 was ﬁnally calculated by multiplying
the percentage and the intensity score. The median value of
the total score was calculated. ADAM8 protein expression
levels were further classiﬁed as low (total score value less than
median level) and high (total score value equal or greater than
median level). Endostatin expression was evaluated according
to a previous work [24]. Cases were considered positive when
P10% of tumor cells showed positive expression.
Statistical analysis
The software of SPSS version 11.0 for Windows (SPSS Inc.,
IL, USA) was used for statistical analysis. The Chi-square test
was used to show differences of categorical variables. Patient
survival and their differences were determined by Kaplan–
Meier method and log-rank test. Cox regression was carried
out for multivariate analysis to assess the speciﬁc impact of
each variable on survival in the presence of other variables.
Only variables of signiﬁcant value from the univariate analysis
were entered into the Cox regression analysis. A p-value 60.05
was considered statistically signiﬁcant.
Results
ADAM8 and endostatin expression and their correlations with
clinicopathological features in primary osteosarcoma
ADAM8 and endostatin expression were analyzed in osteosar-
coma tissues (n= 61) and in lung metastatic osteosarcoma
lesions (n= 11). ADAM8 expression was mainly localized to
the cytoplasm and plasma membrane of malignant cells. Thetotal ADAM8 expression score range was 0–12 with a median
score was 6. Among 61 osteosarcoma specimens, positive
ADAM8 immunoreactivity was detected in 52 samples
(85.2%) and highly expressed in 33/61 (54.1%) of tumors
(Fig. 1A, B). The statistical analyses revealed signiﬁcant
positive associations between high ADAM8 expression and
tumor size, stage and metastasis (p= 0.036, 0.013, 0.023
respectively). No signiﬁcant associations were observed
between ADAM8 expression and patients’ age, gender, tumor
site or histological subtype (Table 2).
Positive cytoplasmic endostatin expression was detected in
45.9% (28/61) of Primary tumors. Positive endostatin
expression in tumor associated blood vessels was also found
(Fig. 1C, D). The expression of endostatin was signiﬁcantly
correlated with tumor size, tumor stage and the presence of
distant metastases (p= 0.035, 0.012, 0.024 respectively). In
contrast, no signiﬁcant correlation was detected between
endostatin expression and other clinicopathological features
(Table 2).
ADAM8 and endostatin expression in pulmonary metastatic
lesions
All pulmonary metastatic osteosarcoma were ADAM8
positive. Nine cases out of eleven (81.8%) had high ADAM8
expression (Fig. 1E) while 2/11 (18.2%) had low expression.
Concerning endostatin expression, 4/11 (36.4%) of metastatic
lesions were positive (Fig. 1F). As shown in Table 3, no signif-
icant differences were detected between the primary osteosar-
coma cases and the pulmonary metastatic lesions regarding
ADAM8 and endostatin expression (p= 0.086 & 0.558 respec-
tively). However, a trend toward a higher ADAM8 expression
in pulmonary metastatic lesions compared to primary tumors
was observed.
The relationship between ADAM8 and endostatin expression in
primary and pulmonary metastatic osteosarcoma
A signiﬁcant positive association was found between ADAM8
and endostatin expression (p= 0.012) in primary osteosar-
coma cases, where a signiﬁcant proportion of endostatin posi-
tive tumors (71.4%) showed high ADAM8 expression scores.
In pulmonary metastatic lesions, no signiﬁcant association
was observed between both markers (p= 0.237) (Table 4).Prognostic values of ADAM8 and endostatin expression in
osteosarcoma
The median overall survival period was 25 months (range 10–
60 months). The prognostic values of ADAM8 and endostatin
together with other clinicopathological parameters were
evaluated (Table 5). Osteosarcoma cases with high ADAM8
expression were signiﬁcantly related with shorter overall sur-
vival (p= 0.0002) (Fig. 2A). The median OS time for osteosar-
coma patients with high ADAM8 expression was 24.2 months
compared to 60 months in patients with low ADAM8 expres-
sion. Regarding endostatin expression, no signiﬁcant relation
between the expression of endostatin and OS was found
(p= 0.133) (Fig. 2B). Moreover, the survival beneﬁts were
found in patients with smaller tumor size (p= 0.037), lower
Table 2 Associations of ADAM8 and Endostatin expression with clinicopathological features in primary osteosarcoma.
Clinicopathological features N ADAM8 expression score Endostatin expression
Low High p-Value ve +ve p-Value
Age
618 years 33 17 (51.5%) 16 (48.5%) 0.340 20 (60.6%) 13 (39.4%) 0.268
>18 years 28 11 (39.3%) 17 (60.7%) 13 (46.4%) 15 (53.6%)
Gender
Male 38 15 (39.5%) 23 (60.5%) 0.195 19 (50%) 19 (50%) 0.409
Female 23 13 (56.5%) 10 (43.5%) 14 (60.9%) 9 (39.1%)
Tumor site
Extremities 54 25 (46.3%) 29 (53.7%) 0.864 28 (51.9%) 26 (48.1%) 0.328
Axial 7 3 (42.9%) 4 (59.1%) 5 (71.4%) 2 (28.6%)
Tumor type
Osteoblastic 39 16 (41%) 23 (59%) 0.256 21 (53.8%) 18 (46.2%) 0.429
Chondroblastic 17 8 (47.1%) 9 (52.9%) 8 (47.1%) 9 (52.9%)
Fibroblastic 5 4 (80%) 1 (20%) 4 (80%) 1 (20%)
Tumor size
68 cm 24 15 (62.5%) 9 (37.5%) 0.036 17 (70.8%) 7 (29.2%) 0.0.035
>8 cm 37 13 (35.1%) 24 (64.9%) 16 (43.2%) 21 (56.8%)
Stage
IA 6 5 (83.3%) 1 (16.7%) 0.013 5 (83.3%) 1 (16.7%) 0.012
IB 7 6 (85.7%) 1 (14.3%) 7 (100%) 0
IIA 10 5 (50%) 5 (50%) 6 (60%) 4 (40%)
IIB 26 10 (38.5%) 16 (61.5%) 12 (46.2%) 14 (53.8%)
III 12 2 (16.7%) 10 (83.3%) 3 (25%) 9 (75%)
Metastasis at diagnosis
No 49 26 (53.1%) 23 (46.9%) 0.023 30 (61.2%) 19 (38.8%) 0.024
Yes 12 2 (16.7%) 10 (83.3) 3 (25%) 9 (75%)
Test of signiﬁcance: Chi-square test and Fisher’s exact test. p-value 60.05 is considered signiﬁcant.
Table 3 Comparison between primary and pulmonary metastatic osteosarcoma cases regarding ADAM8 and Endostatin expression.
Variable Lesions p-Value
Primary osteosarcoma (n= 61) Pulmonary metastatic lesion (n= 11)
ADAM8 expression score
Low 28 (45.9%) 2 (18.2%) 0.086
High 33 (54.1%) 9 (81.8%)
Endostatin expression
Negative 33 (54.1%) 7 (63.6%) 0.558
Positive 28 (45.9%) 4 (36.4%)
Test of signiﬁcance: Chi-square test and Fisher’s exact test. p-Value 60.05 is considered signiﬁcant.
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(p< 0.0001) for OS.
Multivariate Cox regression analysis, enrolling the above
mentioned signiﬁcant parameters, demonstrated the value of
ADAM8 expression for predicting OS of osteosarcoma
patients. High ADAM8 expression and the presence of
metastasis at diagnosis were identiﬁed as the independent poor
prognostic factors for OS (p= 0.017 and 0.003 respectively) of
patients with osteosarcoma. ADAM8 expression displayed a
powerful efﬁcacy in predicting outcome, where it had compa-
rable hazard ratio (HR) with metastasis at diagnosis in reﬁning
OS. High ADAM8 expression score was shown to adversely
inﬂuence OS with a HR of 4.549 (95% CI 1.313–15.759),representing an increase in the risk of dying of osteosarcoma
patients (Table 6).
Discussion
Accumulating evidence has demonstrated ADAM8
overexpression in a variety of human tumors [9–12,23].
The current study identiﬁed abundant ADAM8 expression
in osteosarcoma and osteosarcoma derived lung metastases.
Herein, positive ADAM8 expression rate was 85.2% in pri-
mary osteosarcoma. High ADAM8 expression scores were
observed in 54.1% of tumors. This ﬁnding was in agree-
ment with a previous study, which found that 88.4% of
Table 4 Association between ADAM8 and Endostatin expression in primary osteosarcoma and pulmonary metastatic osteosarcoma.
ADAM8 expression score v2 Phi p-Value
Endostatin expression Low High
Primary osteosarcoma n = 61
Negative 20 (60.6%) 13 (39.4%) 6.260 0.320 0.012
Positive 8 (28.6%) 20 (71.4%)
Pulmonary metastatic osteosarcoma n = 11
Negative 2 (28.6%) 5 (71.4%) 1.397 0.356 0.237
Positive – 4 (100%)
Test of signiﬁcance: Chi-square test and Fisher’s exact test. p-Value 60.05 is considered signiﬁcant. High association: Phi >0.5; moderate
association: Phi = 0.3–0.5; low association: Phi = 0.1–0.3; little if any association: Phi = 0–0.1.
Table 5 Univariate analyses for OS in 61 patients with osteosarcoma.
Item variables Overall survival p-Value
Median OS 12 month rate % (SE) 36 month rate % (SE)
Age
618 years 54.2 76 (0.61) 57 (0.80) 0.455
>18 years 35.8 64 (0.92) 50 (0.84)
Gender
Male 43.4 67 (0.68) 46 (0.69) 0.685
Female 54.9 77 (0.82) 62 (0.87)
Tumor Site
Extremities 48.4 67 (0.49) 50 (0.66) 0.184
Axial 36.0 100 (1.41) 75 (1.40)
Tumor type
Osteoblastic 46.3 69 (0.70) 49 (0.37) 0.666
Chondroblastic 48.7 72 (0.79) 52 (0.71)
Fibroblastic 48.0 80 (1.07) 80 (1.48)
Tumor size
68 cm 60.0 86 (1.31) 72 (1.27) 0.037
>8 Cm 35.9 60 (0.44) 40 (0.53)
Stage
IA 60.0 82 (1.10) 82 (1.52) <0.0001
IB 48.0 100 (1.41) 78 (1.47)
IIA 57.0 100 (1.41) 80 (1.52)
IIB 47.1 79 (0.85) 49 (0.74)
III 18.1 9 (0.09) *
Metastasis at diagnosis
No 60.0 86 (0.93) 64 (0.97) <0.0001
Yes 18.1 9 (0.9) *
ADAM8
Low 60.0 96 (1.34) 76 (1.48) 0.0002
High 24.2 50 (0.36) 34 (0.34)
Endostatin
ve 58.0 80 (0.85) 66 (0.85) 0.133
+ve 36.6 59 (0.60) 34 (0.54)
Log rank test was used; p-value 60.05 is considered signiﬁcant; OS: overall survival, DFS: disease free survival, SE: standard error.
* The maximum follow up time was less than 36 months.
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59.4% had high expression scores [23]. In pulmonary
metastatic osteosarcoma lesions, this study noticed higher
ADAM8 expression scores compared to primary tumors,
indicating ADAM8 up-regulation during tumourigenesis
and progression of this tumor.
The present work also, demonstrated signiﬁcant associa-
tions between high ADAM8 expression and large tumor size,
advanced stage as well as metastases. Moreover, a statisticallysigniﬁcant relation between high ADAM8 expression and
unfavorable OS by univariate analysis was found. Multivariate
analysis conﬁrmed that high ADAM8 expression was an
independent predictor for poor OS. Recently, the association
of ADAM8 up-regulation with aggressive tumor features as
well as poor patients’ prognosis has also been determined by
several studies [9–12,23].
ADAM8 is a crucial player in tumorigenesis and metastatic
spread of malignant tumors. It facilitates the release of
Figure 2 (A)–(D): Kaplan Meier analysis of overall survival in
osteosarcoma patients according to ADAM8 (A) and endostatin
(B) expression in osteosarcoma tissue samples.
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inducing angiogenesis and continued tumor growth. It also
activates b1-integrin on the tumor cells permitting their
attachment to the vascular endothelium and entry into the cir-
culation thus, increasing the numbers of circulating tumor cells
and the risk of developing metastases [12].
Tumor progression and metastasis, in large part, depend on
angiogenesis. Several inhibitors of angiogenesis have been
identiﬁed. Endostatin represents one of the most potent
negative regulators of angiogenesis, which exhibits speciﬁc
inhibitory action on the proliferation, migration, and tube
formation of endothelial cells [14].
The generation of endostatin by several human tumors has
been reported in the literature [4,16,24–26]. In this study,
positive cytoplasmic endostatin expression was detected in
45.9% of tumors, which was consistent with previous studies
demonstrating cytoplasmic endostatin expression in the tumorTable 6 Multivariate analyses for OS in 61 patients with osteosarc
Variables B SE
ADAM8 1.515 0.634
Metastasis at diagnosis 2.471 0.821
Tumor size 0.33 0.718
Stage 0.029 0.457
B: regression coefﬁcient, SE: standard error, HR: hazard ratio, CI: conﬁcells of osteosarcoma, breast, hepatocellular and oral squa-
mous cell carcinomas [4,16,24–26], suggesting that the source
of endostatin may be partially derived from these types of
tumor cells. However, our results were inconsistent with a
previous study [15] that reported restricted expression of endo-
statin to tumor associated blood vessels with no expression by
tumor cells of malignant gliomas. Another study [18] demon-
strated stage dependent localization of endostatin in bladder
carcinoma, being localized to tumor associated blood vessels
in superﬁcial carcinoma while strongly expressed in cancer cells
in muscle-invasive bladder carcinoma. These discrepancies
could be attributed to several factors such as tumor histology,
stage and primary site of the tumor. In addition, differences in
laboratory detection methods as well as variations in immuno-
reactivity to different endostatin antibodies used in different
studies could be responsible for these variations.
In pulmonary metastatic osteosarcoma lesions, the present
study demonstrated that endostatin expression rates were
relatively reduced compared to primary tumors however;
endostatin expression rates did not differ signiﬁcantly between
primary osteosarcoma and pulmonary metastatic lesions. In
agreement with our ﬁnding, a previous study demonstrated
no signiﬁcant difference in endostatin immunoreactivities
between primary oral squamous cell carcinomas and meta-
static nodes; although a trend for diminished endostatin
expression in the metastatic nodes was observed [26]. Whether
primary tumors may generate more endostatin than metastatic
tumors, an issue needs further elucidation on a larger scale of
primary and metastatic tumors.
As endostatin is a potent anti-angiogenetic factor, one
would expect decreased endostatin levels during tumor
progression. Interestingly, the present study demonstrated sig-
niﬁcant associations between the expression of endostatin and
increased tumor size, stage and presence of metastasis. These
ﬁndings are in agreement with previous studies in osteosar-
coma [24], hepatocellular carcinoma [16] and gliomas [15].
Similarly, other studies reported an association between
increased serum endostatin levels and aggressive tumor
features as well as unfavorable prognosis [17,18,27,28].
However, our ﬁndings are inconsistent with two studies
that observed a signiﬁcant association between endostatin
expression and decreased metastatic potential in oral
squamous cell carcinoma [26] and osteosarcoma [4] cases.
However, the latter reported a signiﬁcant association between
positive endostatin expression and poor differentiation in
osteosarcoma.
Recent studies have provided reasonable evidence that
explain why the anti-angiogenic factor, endostatin, is associ-
ated with aggressive features in malignant tumors. During
the process of the angiogenesis, large amounts of angiogenic
factors are secreted from malignant cells to promote angio-
genic phenotype of malignant tumors. The increased levels ofoma.
p-Value HR (95% CI)
0.017 4.549 (1.313–15.759)
0.003 11.836 (2.370–59.104)
0.964 1.033 (0.253–4.218)
0.950 1.029 (0.420–2.521)
dence interval; p-value 60.05 is considered signiﬁcant.
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compensatory response to regulate the angiogenesis balance
[4,29]. Elevated levels of endostatin in aggressive tumors are
also, related to the proteolytic cleavage of endostatin
precursor, collagen XVIII, mediated by elevated matrix
metalloproteinases (MMPs) family members in these tumors
[18,30]. Given the complexity of endostatin generation and
function, future studies are warranted to deﬁne the mecha-
nisms underlying endostatin up-regulation and function during
osteosarcoma progression.
On studying the association of ADAM8 and endostatin
expression, the current study identiﬁed signiﬁcant association
between both markers in primary osteosarcoma cases where a
great proportion of endostatin positive tumors showed high
ADAM8 expression scores. To the best of our knowledge,
the direct relation between ADAM8 and endostatin has not
been discussed in previous literature. Various proteases such
as MMP family members have been implicated in endostatin
generation from its precursor collagen type XVIII [30]. As the
process of angiogenesis is accompanied by intensive remodel-
ing of the extracellular matrix, the degradative action of
various proteases likely leads to increased generation of endo-
statin from collagen type XVIII, one of the constituents of
basement membranes as a local control mechanism for the
regulation of angiogenesis [18,30,31]. These reports strongly
suggest that elevated endostatin level is related to the prote-
olytic cleavage of collagen XVIII by proteases. ADAM8
was reported to have proteinase activity as its metalloprotein-
ase sequence with the catalytic metalloproteinase domain of
MMPs family [6]. ADAM8 expression was also, detected
under pathological conditions characterized by extracellular
matrix remodeling such as cancer [7], suggesting that its
metalloproteinase activity may partially participate in the
increased generation of endostatin from collagen type XVIII
during cancer progression. In support of our interpretation,
high serum endostatin level was signiﬁcantly correlated with
elevated MMP-7 concentrations in bladder cancer [18].
However, the association between ADAM8 and endostatin
expression was not exclusive in this series. We also noticed
that 28.6% of endostatin positive tumors were either
ADAM8 negative or had low ADAM8 expression scores,
indicating that the involvement of other proteases in endo-
statin production should be considered.
In conclusion, the current work showed that ADAM8
was upregulated in primary osteosarcoma tissues and in
metastatic pulmonary lesions. Its overexpression was associ-
ated with aggressive malignant features. Positive endostatin
expression was also, correlated with aggressive tumor
features, indicating the role of ADAM8 and endostatin in
osteosarcoma progression. Our ﬁndings also, suggest
ADAM8 as a good marker for advanced and metastatic
osteosarcoma. More importantly, ADAM8 expression status
was an independent prognostic indicator for predicting the
OS in osteosarcoma patients. The relation between ADAM8
and endostatin and the role of various proteases in genera-
tion of endostatin need further investigation on a larger
scale of tumors.Conﬂict of interest
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